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ABSTRACT: Natural and engineered phages have been used in
many applications, but their use to deliver user-defined genetic
cargoes has been hampered by contamination with replicative
phage, restricting use of the technology beyond the laboratory.
Here we present a method to produce transducing particles
without contamination. In addition, we demonstrate the use of a
helper phage-free transducing particle preparation as an anti-
microbial agent. This will pave the way for the development of new
phage-based technologies with greater scope than lytic phage
therapy.
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Transduction is a process in which bacterial nucleic acidsare transferred from one bacterial cell to another by
bacteriophage structural proteins.1 The assembly comprising
virion proteins and the nonbacteriophage nucleic acid cargo is
called a transducing particle. In the preparation of transducing
particles, structural proteins are supplied by a helper
bacteriophage. Typically, cells containing the cargo to be
transduced are infected with helper bacteriophage, which
carries out its lytic reproductive cycle, during which, some
nonbacteriophage nucleic acid is packaged into bacteriophage
capsids, yielding transducing particles. Upon cell lysis, helper
phage progeny and transducing particles are released, which
can infect recipient cells, either continuing the helper
bacteriophage lytic cycle or completing transduction, respec-
tively.
Bacteriophage transduction has been proposed as an
alternative to bacteriophage therapy in which lytic phages are
used, for the following reasons: (1) Bacteriophage transduction
is independent of the processes that occur within the recipient
cell as there is no requirement for the interaction of host/
parasite gene networks for replication, virion assembly, and cell
exit, as with native bacteriophages.2−4 Thus, the specificity of a
transducing particle could be reprogrammed to new hosts
solely on the basis of receptor recognition and DNA injection,
without the need to identify a cognate bacteriophage, as would
be required for traditional bacteriophage therapy;5 (2) As
transducing particles are nonreplicative, their route to market
may be simpler than that of whole bacteriophages because,
clearly, the release of nonreplicative transducing particles is
more easily controllable than whole bacteriophages; (3)
Transduction is more flexible than bacteriophage therapy
using lytic phages. While lytic bacteriophage therapy is
restricted to killing bacterial cells, transduction could be used
to introduce a variety of user-defined genetic constructs to
bacterial cells, including antibiotic sensitization cassettes,
antigens for the in situ production of vaccines, lysins to
selectively kill the targeted bacteria, or biofilm-degrading
enzymes, among others. Because of the many attractive
features of bacteriophage transduction, it is being actively
researched to develop novel technologies and is being used as a
research tool.5−8 It should be noted, however, that
bacteriophage transduction carries the caveat that since the
particles are nonreplicative, they must be administered to the
patient in higher doses than required for bacteriophage therapy
using replicative lytic bacteriophages.
We are interested in P2 bacteriophage as a candidate for
bacteriophage transduction for the following reason: Its
nonspecific DNA injection mechanismthe step following
the receptor-specific adsorption stepsuggests it could be
reprogrammed by mutagenesis to recognize and deliver DNA
to alternative hostsas was demonstrated with the related R-
type pyocinsbroadening its range of applications.9−11
However, P2 bacteriophage, once established as a prophage,
is noninducible, thus it cannot perform as a helper
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bacteriophage in transducing particle preparation, since the
necessary structural proteins will not be expressed.12 Thus, the
lytic variant P2vir1 must be used as a helper bacteriophage for
transduction.13 However, this method yields preparations of
transducing particles that are contaminated with helper
bacteriophage (Figure 1A).14 Heat-inducible variants of the
P2 lysogen can be used as helper bacteriophage to produce
transducing particles.15,16 However, these retain the P2
packaging signal and thus retain the possibility of helper
bacteriophage contamination in the transducing particle
preparation.
Helper bacteriophage contamination renders transducing
particle preparations unsuitable for clinical trials or pharma-
ceutical use, as it would be necessary to demonstrate the safety
and efficacy of the transducing particles and the helper phage
separately and in combination.17 If they cannot be separated,
they cannot be tested in isolation.
Contamination by helper bacteriophage is not unique to the
preparation of P2-derived transducing particles. Bikard et al.
used the Staphylococcus aureus bacteriophage ΦNM1 as a
helper bacteriophage to package a ΦNM1-derived phagemid.6
In this system, 24% of the total bacteriophage particles
contained the user-defined DNA and the remaining 76% were
wild-type helper bacteriophage contaminants. Because of this
contamination, experiments had to be performed using an
immune bacterial strain (ΦNM1 lysogen) as the recipient
strain, to prevent lysis by the contaminant.
In addition, the preparation of T7 bacteriophage-derived
transducing particles yields contaminated preparations.5,18
Yosef et al. produced transducing particles with a tail fiber-
deficient variant of T7 as the helper bacteriophage.5 However,
despite this measure, when delivering the cargo, the T7-
insensitive E. coli variant ΔtrxA had to be used to prevent cell
lysis by the helper bacteriophage contamination. Chung and
Hinkle reported a ∼1:1 ratio of transducing particles to helper
bacteriophage yielded by this method and removed the
contamination by cesium chloride sedimentation.18 An ideal
method would have no helper bacteriophage contamination in
the first place.
To eliminate contamination, others have avoided helper
bacteriophage altogether and opted to genetically modify a
bacteriophage instead, using this to deliver genetic cargo.
Edgar et al. developed a system for the sensitization of
pathogenic bacteria to antibiotics, delivering genetic material
to recipient cells with λ bacteriophage-derived virions.19 The
genetic material delivered contained all the information
required to produce infectious virions and the user-defined
genetic cargo. Furthermore, Yosef et al. modified the genome
of a λ prophage by homologous recombination.20 Upon
induction of the modified prophage, bacteriophage particles
were produced and later used to introduce the modified DNA
into a recipient bacterial strain. Again, the particles contained
all the information required to produce infectious virions and
the user-defined genetic cargo. While these two approaches
yield preparations of particles that contained no helper
bacteriophage, as they contained a self-replicating, antibiotic
resistance-encoding element, there would likely be regulatory
issues during commercialization. It is thus important to
separate the delivered cargo from the DNA that encodes the
proteins involved in the bacteriophage reproductive cycle,
which is achieved with a helper bacteriophage.
The helper bacteriophage contamination problem has been
addressed for M13 bacteriophage by supplying bacteriophage
proteins from a plasmid that has no packaging signal, then
packaging a cosmid (plasmid with a packaging signal).21 In
addition, a method to produce helper bacteriophage-free
transducing particles that target Staphylococcus aureus was
recently developed.22 This was achieved by the reengineering
of staphylococcal pathogenicity islands to remove toxin genes,
and the deletion of the small terminase subunit gene from the
genome of the cognate helper bacteriophage. However, the
issue has not been addressed for P2 bacteriophage-based
transduction.
Presented here is a method to produce pure preparations of
P2 bacteriophage-based transducing particles. This is achieved
by replacing the packaging signal of a P2 prophage with the
delta and epsilon genes from the satellite bacteriophage P4,
both under the control of an L-rhamnose-inducible promoter
(Figure 1B). The delta gene product is a transcriptional
activator of the P2 late genes (lysins and structural proteins),
and the epsilon gene product is a derepressor of the same
genes.23−25 Thus, delta and epsilon trigger the P2 prophage to
act as a helper bacteriophage (Figure 1B). This genetic
manipulation simultaneously renders the late genes of the
lysogen, and thus the production of transducing particles,
chemically inducible and abolishes the ability of the P2
Figure 1. Comparison of methods to produce preparations of transducing particles. (A) Method using P2vir1 as the helper bacteriophage. (B)
Method using Escherichia coli strain lysogenized with cos site deficient P2 prophage that encodes chemically inducible P4 bacteriophage proteins as
the helper bacteriophage.
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genome to be packaged in the resulting bacteriophage particles,
since the lysogen has no packaging signal. This method yields
transducing particle titers of up to 1.8 × 107 particles·mL−1
with no contamination by helper bacteriophage.
The method developed here enables for the first time the
chemically induced production of transducing particles without
helper P2 contamination. This could be used to deliver user-
defined genetic cargo to a programmable host tropism, for a
range of biotechnological purposes. This will enable the
production of pharmaceutically suitable preparations, thus
making it possible now to deploy P2-based transducing
particles beyond the laboratory bench.
■ RESULTS AND DISCUSSION
Three modified prophages were created by recombineer-
ing.26−28 The prophage to which all genetic modifications were
made in order to generate the mutants here was P2del1
(encoded within Escherichia coli C-5545), which has the del1
mutation to permit nonlethal expression of the lambda red
recombinases required for recombineering (Figure 2A,B).
P2Δcos (encoded within E. coli C-5545 Δcos) (Figure 2C) is a
P2 prophage with the cos site replaced by a trimethoprim
resistance cassette; P2Δcosδ (encoded within E. coli C-5545
Δcosδ) (Figure 2D) is the same as P2Δcos but encodes P4
bacteriophage protein delta under the control of a rhamnose-
inducible promoter; P2Δcosδε (encoded within E. coli C-5545
Δcosδε) (Figure 2E) is the same as P2Δcosδ, but the
trimethoprim resistance cassette was replaced by P4 bacter-
iophage protein epsilon expressed in the same transcript as
delta, and a hygromycin resistance cassette. The various
combinations of delta and epsilon were necessary to allow their
individual contributions to prophage late gene induction to be
determined. Correct assembly of the strains was confirmed by
Sanger sequencing.
To compare the method presented here to the method using
P2vir1 as helper bacteriophage, a standard cosmid was
constructed for use in both protocols, pACK57. The
pACK57 cosmid was designed such that its size is an integer
fraction of the size of the P2 genome, to facilitate packaging of
whole multiples of pACK57 into transducing particles. (A
limitation of P2 as a transduction vector is that transduction
efficiency is optimal when the size of the transduced DNA is an
integer fraction of the size of the P2 genome. This must thus
be taken into consideration during design. A headful packaging
bacteriophage would not have this limitation.) In addition, the
high copy number pUC57 vector was chosen to maximize the
number of cosmids available for packaging. A kanamycin
resistance cassette was included to enable selection of
transductants based on antibiotic resistance. Finally, the cos
site from P4 bacteriophage was inserted by Gibson
assembly.29,30 Construction of the cosmid was confirmed by
Sanger sequencing.
As the P2vir1-derived transducing particle preparations were
anticipated to contain helper bacteriophage contamination, all
transduction experiments were performed using E. coli Δrep as
the recipient strain, since it is immune to P2vir1. Transduction
of pACK57 to E. coli Δrep using P2vir1 as the helper
bacteriophage yielded 2.03 × 106 TFU·mL−1 (s = 2.9 × 105
TFU·mL−1; n = 3) (Figure 3). Transduction of pACK57 to E.
coli Δrep using P2Δcosδ as the helper bacteriophage yielded
3.85 × 106 TFU·mL−1 (s = 2.72 × 106 TFU·mL−1; n = 6)
(Figure 3). Transduction of pACK57 to E. coli Δrep using
P2Δcosδε as the helper bacteriophage yielded 1.78 × 107
TFU·mL−1 (s = 6.38 × 106 TFU·mL−1; n = 6) (Figure 3). It
might be reasoned that the transduction from the defective
lysogen strains was due to spontaneous late gene activation,
rather than expression of the P4 bacteriophage-derived genes.
To rule this out, pACK57 was transduced to E. coli Δrep using
P2Δcos as the helper bacteriophage. This yielded 1.50 × 105
TFU·mL−1 (s = 1.04 × 105 TFU·mL−1; n = 6) (Figure 3). This
level of transduction is significantly lower than when the other
defective prophages were used (P = 0.029 when compared to
P2Δcosδ; P = 0.0016 when compared to P2Δcosδε) that
encode the P4 bacteriophage-derived proteins, indicating that
their expression is indeed effective in inducing the P2
bacteriophage late genes. The level of transduction when
using P2Δcosδ as the helper bacteriophage was not
significantly different to the level of transduction using
P2vir1 (P = 0.20). However, the level of transduction using
P2Δcosδε as the helper bacteriophage was significantly higher
than the level of transduction when using P2vir1 (P = 0.0026)
and significantly higher than the level of transduction when
Figure 2. Relevant genotypes of bacteriophage genetic constructs. (A)
Region surrounding the cos site in wild type P2 prophage. (B) The
same region in del1 mutant P2, which is present in Escherichia coli C-
5545. (C) The same region in P2Δcos (encoded within Escherichia
coli C-5545 Δcos). (D) The same region in P2Δcosδ (encoded within
Escherichia coli C-5545 Δcosδ). (E) The same region in P2Δcosδε
(encoded within Escherichia coli C-5545 Δcosδε).
Figure 3. Comparison of transduction level with P2vir1 and P2Δcos
±δ±ε methods with the pACK57 cosmid and Escherichia coli Δrep as
the recipient strain. *P ≤ 0.05. **P ≤ 0.01.
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using P2Δcosδ (P = 0.003), demonstrating the necessity of the
introduction of the epsilon gene to the prophage.
To test whether the removal of the cos site from the
prophage had had the intended effect of eliminating helper
bacteriophage contamination, it was next necessary to assess
the preparations by plaque assay (Figure 4).
To quantify the contamination by helper bacteriophage
produced by the different methods, transducing particle
preparations were subjected to plaque assay against the P2-
sensitive E. coli EMG2. This revealed 5.06 × 106 PFU·mL−1 (s
= 6.4 × 105 PFU·mL−1; n = 3) in the sample prepared with
P2vir1 as the helper bacteriophage (Figure 4). The trans-
duction efficiency (%) (= [TFU/(TFU + PFU)]·mL−1 × 100)
when using P2vir1 was thus 28.7% (s = 3.2%; n = 3) (Figure
5).
Plaque assays of samples prepared using P2Δcos as the
helper bacteriophage revealed 3.6 × 104 PFU·mL−1 (s = 1.8 ×
104 PFU·mL−1; n = 6) (Figures 4 and 5). The transduction
efficiency when using P2Δcos was thus 65.1% (s = 30.6%; n =
6) (Figures 4 and 5). We hypothesized that this contamination
was due to reconstitution of the wild type sequence of the
packaging signal of the prophage by recombination between
the pACK57 cosmid and the prophage during bacterial growth.
To test this, the transducing particle preparation procedure
was repeated in the absence of pACK57, thus removing the
substrate for homologous recombination. Plaque assays using
such lysates always revealed 0 PFU·mL−1 (n = 6) (Figure 4
“P2Δcos (no cosmid)”), which is consistent with our
hypothesis.
Plaque assays of samples prepared using P2Δcosδ/δε as the
helper bacteriophage always revealed 0 PFU·mL−1 (n = 6)
(Figure 4). Transduction efficiency with the newly presented
method was thus 100% (Figure 5).
We further hypothesize that the absence of reconstitution of
the wild type sequence of the packaging signal of the prophage,
and thus the absence of plaque-forming units, when using
P2Δcosδ/δε might be explained by the large insertions of
DNA in the former locus of the cos site. We hypothesize that
the disparity in sizes of potential recombination substrates
caused by the insertion of the delta/epsilon genes might reduce
the efficiency of recombination to an extent that prophage
reconstitution was never seen during the transducing particle
production procedure.
To detect encapsidated, poorly replicative helper bacter-
iophage genomes, which would not be detectable by plaque
assay, lysates were subjected to deoxyribonuclease (DNase)
treatment, to digest DNA not contained within transducing
particles, then PCR was performed to identify the packaged
DNA (Figure 6). Two pairs of primers were designed: one to
amplify a 2010 bp region within the P2 genome (P2_GpH_F/
R, Table S5); and the other to amplify a 500 bp region within
pACK57 (pk2_ins_F/R, Table S5), enabling distinction
between the packaged DNA cargos. P2 sequence was detected
only in the lysate prepared using P2Δcos as the helper
bacteriophage (Figure 6B). The same PCR was performed
Figure 4. Plaque assays. Comparison of level of helper contamination
in transducing particle preparations. The pACK57 cosmid was
transduced and E. coli EMG2 was the indicator bacterial strain. **P
≤ 0.01. N.D., not detected (lower limit of detection is 1 PFU·mL−1).
Figure 5. Comparison of transduction efficiencies of different helper
bacteriophages. Transduction efficiency (%) calculated as (TFU/
(TFU+PFU))·mL−1 × 100.
Figure 6. PCR to detect encapsidated helper bacteriophage genomes.
(M) Molecular-weight size marker. (A) P2vir1 positive control
performed with primers targeting P2 sequence. (B) P2Δcos lysate.
(C) P2Δcosδ lysate. (D) P2Δcosδε lysate. (E) P2Δcos (no cosmid)
lysate. (i) PCR performed with primers targeting P2 sequence. (ii)
PCR performed with primers targeting cosmid (pACK57) sequence.
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using P2vir1 as the template and is included as a positive
control (Figure 6A). In all instances where pACK57 was
intended to be present, it was detected, as indicated by the
presence of a 500 bp amplicon (Figure 6B−D). Lysates of all
producer strains were positive for both P2 and pACK57
sequences prior to DNase treatment (data not shown), thus
the absence of P2 sequence and presence of pACK57 sequence
in the DNase-treated samples indicates that the pACK57 DNA
was packaged within transducing particles. Furthermore, P2
sequence was not detected when the cosmid was excluded
from the E. coli C-5545 Δcos producer strain (Figure 6E),
aligned with the result of the plaque assay in Figure 4, which
indicated no production of replicative bacteriophage when the
cosmid was absent during production. To summarize, in
lysates prepared using P2Δcosδ or P2Δcosδε, packaged helper
bacteriophage genomes were not detected by PCR, which
clearly detected the cosmid, strongly suggesting the absence of
encapsidated helper bacteriophage genomes.
The results presented in Figures 3−6 demonstrate that our
newly developed method is capable of yielding preparations of
transducing particles at titers higher than the established
P2vir1-based method,14 while yielding no helper bacteriophage
contamination.
To demonstrate the potential therapeutic utility of
bacteriophage transduction, we sought to create an anti-
bacterial preparation of transducing particles free of replicative
helper bacteriophage. We thus designed and assembled a
cosmid based upon bacteriophage P4. In this assembly,
nucleotide positions 247−4065 of the genome of bacterio-
phage P4 (NCBI reference sequence: NC_001609.1) were
replaced by a nucleotide sequence of equal size, which encodes
the Escherichia phage MS2 gpL lysis protein,31 the Enter-
obacteria phage Phi X174 gpE lysis protein,32 and the Lambda
LysS, LysR, and Rz lysis proteins under the control of the
promoter PLtetO-1.33−36 To prevent the expression of the
cosmid-encoded lysins during transducing particle production,
we introduced the Marionette cluster,37 which encodes the Tet
repressor, to the producer cell line by P1 transduction,38
repressing expression from the PLtetO-1 promoter. Since the
P4-based cosmid encoded the delta and epsilon proteins of
bacteriophage P4, we used the producer strain that does not
encode these two genes, Escherichia coli C-5545 Δcos. The
cosmid was introduced to the strain by chemical trans-
formation. The transformed cells were then capable of
producing P4-based transducing particles, which in turn
could infect untransformed cells of the same strain, amplifying
the population of transducing particles, with no bacteriophage
P2 contamination. The resulting stock of transducing particles
was then used to deliver the lysin-encoding cosmid to a culture
of lysin-repression-incompetent Escherichia coli EMG2, grown
to optical density at 600 nm (OD600) = 0.2 prior to
transduction. The OD600 and thus growth and/or lysis of the
transduced cells was monitored using a plate reader. A range of
multiplicities of infection (MOI) was screened, from 0.2 to 1.0
in increments of 0.2 (Figure 7A), and from 2 to 10 in
increments of 2 (Figure 7B). When the MOI was between 0.2
and 1.0 inclusive, the bacterial culture was noticeably lysed,
with the extent of lysis correlating with the MOI, but bacterial
growth promptly recovered (Figure 7A). At MOI 2, lysis was
more substantial, with a less noticeable recovery (Figure 7B).
When the MOI was between 4 and 10 inclusive, there was no
substantial effect of MOI on the extent of lysis and no cellular
recovery was observed, suggesting complete or near-complete
bacterial clearance (Figure 7B). Untransduced cells (MOI 0)
grew continually throughout the experiment (Figure 7). In
addition, plaque assays of the transducing particle preparations,
using Escherichia coli EMG2 as the indicator strain revealed no
plaques, confirming that they are nonreplicative (data not
shown). It was thus concluded that the lysis observed following
addition of the transducing particles to the bacterial cells was
due to successful delivery of the nucleic acid cargo and
expression of the lysins.
The results of the experiment shown in Figure 7 thus
demonstrate the potential use of a helper bacteriophage-free
preparation of transducing particles as an antimicrobial agent.
■ CONCLUSION
We have demonstrated here a method to produce helper
bacteriophage-free preparations of transducing particles, a first
for bacteriophage P2. The results presented here are the first
step in the development of several technologies based on the
P2 virion, without using bacteriophage therapy. These
technologies may includebut are not restricted toparticles
that sensitize bacteria to antibiotics, particles that deliver the
genetic material for the expression of antigens for the in situ
production of vaccines, or particles that trigger bacteria to
produce biofilm-degrading enzymes. Combined with directed
evolution of the tropism-determining elements of the P2
virion, the technologies that could be produced could have
very far-reaching impact indeed.
Figure 7. Delivery of lysin-encoding cosmid to bacterial cells. (A) Screen of transducing particle multiplicities of infection between 0.0 and 1.0. (B)
Screen of transducing particle multiplicities of infection between 0 and 10. OD600, optical density at 600 nm. MOI, multiplicity of infection.
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■ MATERIALS AND METHODS
Strains (Bacteria and Bacteriophage). Escherichia coli C-
5545 and E. coli C-1a were kindly provided by Gianni Deho,̀
University of Milan. E. coli Δrep was obtained from the Keio
collection (Plate 29, well 12B; Keio designation: JW5604-1).39
E. coli EMG2 ATCC 23716 was purchased from the American
Type Culture Collection. P2vir1 was kindly provided by Goran
Jovanovic, Imperial College London. P1vir1 was kindly
provided by Baojun Wang, University of Edinburgh. All
bacterial/bacteriophage strains used are summarized in Tables
S1 and S2. All bacterial strains original to this study will be
made available via the Addgene bacterial strains repository.
Plasmids/Cosmids. The plasmid pORTMAGE-2 was a
gift from Csaba Paĺ (Addgene plasmid #72677, http://n2t.net/
addgene:72677; RRID, Addgene_72677) and was used to
supply lambda red recombinases during the recombineering
procedure.40 The pACK57 cosmid was constructed by Gibson
assembly,30 deriving the cos site from bacteriophage P4
(Figure S1; Table S3).29 All plasmids and cosmids original to
this study will be made available via the Addgene plasmid
repository.
Recombineering. To edit the genome of the P2 lysogen,
recombineering was performed as published.26−28 To eliminate
lambda-P2 interference, a P2 lysogen variant was used as the
strain from which all variants here were derived (Escherichia
coli C-5545, which encodes the del1 mutationthe deletion of
the old genepreventing cell death upon induction of lambda
proteins).27,28,41−45 Linear oligonucleotides (Table S4) were
used as the recombineering substrate and were purchased from
Integrated DNA Technologies.
Preparation of Transducing Particles−Prophage
Used as Helper Bacteriophage. When using modified/
wild type P2 prophage as helper bacteriophage, overnight
cultures of the lysogenic production strains containing the
cosmid were grown at 30 °C with aeration in 1 mL of Luria−
Bertani (LB) broth supplemented with 50 μg·mL−1 kanamycin
(to maintain the cosmid), inoculated with glycerol stock stabs.
The following day, the overnight cultures were diluted (2 μL of
culture in 10 mL of media) in LB broth supplemented with
0.2% L-Rhamnose (to induce of δ/ε genes), 15 mM EDTA (to
prevent readsorption of transducing particles to cells or cell
debris) and 50 μg·mL−1 kanamycin. Cultures were grown for
24 h at 30 °C with aeration. Chloroform was then added to
10% final concentration. Following brief (∼5 s) mixing by
vortex, cell debris was pelleted by centrifugation at 2490g for 8
min. The supernatant was aspirated with a serological pipet
without disturbing the pellet and then passed through a 0.2 μm
syringe filter to remove remaining cells. The pellet was then
discarded, and the filtered supernatant was stored at 4 °C.
Preparation of Transducing Particles−P2vir1 Used as
Helper Bacteriophage. When P2vir1 was used as the helper
bacteriophage, published protocols were followed.14 The
production strain was Escherichia coli C-1a containing the
pACK57 cosmid, and LB broth was supplemented with 50 μg·
mL−1 kanamycin.
Transductant-Forming Units (TFU) Assays. Recipient
strain (Escherichia coli Δrep) was grown overnight at 37 °C
with aeration in LB. Prior to addition of transducing particles,
CaCl2 was added to the overnight culture, and the culture was
incubated at 37 °C with aeration for 15 min. To 100 μL of
overnight culture, 100 μL of transducing particle dilution were
added. The mixture was mixed by inversion (∼5 times),
incubated for 10 min at 37 °C without aeration to allow
binding of transducing particles to cells, then incubated at 37
°C for 30 min with aeration to allow for expression of
antibiotic resistance proteins. The mixtures were then spread
on LB agar supplemented with 50 μg·mL−1 kanamycin and
incubated overnight at 37 °C. Transductant-forming units were
enumerated the following day by counting colonies and
expressed as TFU·mL−1.
Plaque-Forming Units (PFU) Assays. Plaque-forming
units were enumerated by plaque assay, using Escherichia coli
EMG2 as the indicator strain. To 100 μL of Escherichia coli
EMG2 overnight culture in LB supplemented with 5 mM
CaCl2 (to promote bacteriophage adsorption to the host),
14
100 μL of lysate dilution was added. Following brief mixing
(approximately two seconds on a vortex mixer), the mixture
was incubated stationary at 37 °C for 10 min. Three milliliters
of soft agar (LB supplemented with 0.75% agar), melted and
stored at 42 °C, was added to the mixture, which was briefly
mixed by swirling by hand, then poured onto an LB agar (+50
μg·mL−1 kanamycin) plate, which had been preheated to 37
°C. The plate was swirled for even coverage by the soft agar
mixture, left to solidify at room temperature for 5 min, then
incubated stationary at 37 °C overnight. Plaques were counted
the following day and expressed as PFU·mL−1.
Deoxyribonuclease Treatment of Lysates. Genomic
DNA in the bacteriophage lysates was digested with
Deoxyribonuclease I from divine pancreas (Sigma Life
Science) as per the manufacturer’s instructions (1 μL of
lysate; 1 μL of 10X Buffer; 1 μL of DNase; 7 μL of water).
Digestion was allowed to proceed for 15 min at 25 °C. To stop
the reaction, 1 μL of stop solution was added to the reaction
mixtures. Finally, the DNase in the reaction mixtures was
inactivated by incubating the samples at 70 °C for 10 min.
Inactivated reaction mixtures were then stored on ice until
further use.
Polymerase Chain Reaction. PCR was performed using
primers P2_GpH_F/R or pk2_ins_F/R (Table S5), 1 μL of
DNase-treated lysate as the template, and Phusion High-
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